BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...efficacy data cut-off.The trial is evaluating four dose cohorts of AB680 in combination with Abraxane nab-paclitaxel...
BioCentury | Jan 16, 2021
Product Development

Zymeworks showcases >45% confirmed ORRs for anti-HER2 bispecific in biliary, gastroesophageal cancers

...six months.In 24 evaluable patients in the same study treated with zanidatamab in combination with paclitaxel...
BioCentury | Jan 15, 2021
Product Development

Readout for Arcus’ pancreatic cancer program could spur Gilead to exercise option

...of the 17 patients.The trial is evaluating four dose cohorts of AB680 in combination with Abraxane nab-paclitaxel...
BioCentury | Dec 12, 2020
Product Development

Dec. 11 Quick Takes: AZ to run combo trial with Sputnik; plus Phase III hits for Lilly, AbbVie and TG, data from Immutep, NVS, Mycovia, Sarepta and Greenwich

...eftilagimod alpha in combination with paclitaxel led to a survival benefit of 2.7 months versus paclitaxel...
BioCentury | Oct 17, 2020
Product Development

How the PanCAN master protocol could promote innovation in pancreatic cancer

...regimens: FOLFIRINOX or Gemzar gemcitabine plus Abraxane paclitaxel. It’s...
BioCentury | Sep 19, 2020
Product Development

Sept. 18 ESMO roundup: data from Incyte, Autolus, Merck, Alkermes and Daiichi

...SCAC) who have progressed following chemotherapy.  A Phase III trial of retifanlimab with carboplatin and paclitaxel...
BioCentury | Sep 2, 2020

Sept. 1 Quick Takes: House committee to subpoena AbbVie on pricing; plus Athenex, Harmony, AZ, BMS, Novo, and cancer trial guidance

...for Athenex’s breast cancer therapyFDA accepted and granted Priority Review to an NDA for oral paclitaxel...
BioCentury | Aug 12, 2020
Product Development

Aug. 11 Quick Takes: BMS hits, Genentech misses; plus JW-Lyell, CStone, Big Health

...primary endpoint in the Phase III HIBISCUS I induction study.  Last week Genentech said Tecentriq atezolizumab plus paclitaxel missed...
BioCentury | Aug 7, 2020

Aug. 6 Quick Takes: More pressure on China’s U.S. listings; busy Editas; Athenex bestows royalty on Sagard; Longwood, CFF launch incubator and more

...Royalty Partners under which it will receive $50 million upon FDA approval of its oral paclitaxel...
BioCentury | Jul 16, 2020

July 15 Quick Takes: Early access in U.K. for Alnylam RNAi; plus Verrica, CytoDyn, J&J and Roche improve progression-free survival in newly diagnosed advanced ovarian cancer when added to Avastin bevacizumab, paclitaxel...
Items per page:
1 - 10 of 2706